TNFRSF10B and plasma cell myeloma: A combination of two noncompetitive DR5-specific IgG1 antibodies has shown the highest cytotoxic activity in samples from patients with relapsed/refractory multiple myeloma, particularly those previously treated with anti-MM medications, indicating a possible sensitization effect (van der Horst et al., 2021; Overdijk et al., 2019; Di Cristofano et al., 2023; Carter and Rajpal, 2022)